copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Athira Pharma Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million
Pipeline – Athira Pharma Several new compounds are currently in preclinical discovery and development for neurodegenerative diseases and other indications for which Athira believes positive modulation of the neurotrophic HGF system may have therapeutic potential
News – Athira Pharma Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS) May 29, 2024
About – Athira Pharma Mark Litton, PhD — President CEO Mark Litton is President and CEO of Athira Pharma, a position he has held since October 2021 Previously, he served as Athira’s COO since July 2019
Science – Athira Pharma Select Athira Scientific Publications By clicking on the links below, you will access PDF reprints of peer-reviewed publications made available by scientific journals via open-access
Therapeutic Focus – Athira Pharma Deepening C o n n e c t i o n s At Athira, We Are Focused on Addressing Devastating Diseases Where Current Treatment Options Are Limited Breast Cancer Estrogen receptor–positive (“ER⁺”) breast cancer accounts for roughly 70% of all breast cancer cases and relies on estrogen-mediated signaling for tumor growth and survival
Careers – Athira Pharma At Athira, our approach is rooted in building, restoring and maintaining connections Loss of nerve cell connections are the underlying cause for numerous neurological diseases which in turn may result in the loss of personal connections between patients and their loved ones
Patients – Athira Pharma We believe Athira’s unique approach has the potential to change the treatment paradigm to restore neuronal health Athira aims to discover and develop important new therapeutics with the potential to impact a wide range of neurological diseases and conditions
Investors – Athira Pharma With our product candidates, we aim to provide rapid cognitive improvement and alter the course of neurological diseases with our novel mechanism of action Athira is currently advancing its lead therapeutic candidate, ATH-1017, a novel small molecule, for Alzheimer’s Corporate Presentation Press Releases November 10, 2021 November 10, 2021
Contact – Athira Pharma Legitimate email communications from Athira’s hiring team will always come from an email address that ends with “@athira com” or “@app bamboohr com” (our third-party applicant tracking system)